These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27325863)

  • 1. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.
    Hershman DL; Till C; Wright JD; Awad D; Ramsey SD; Barlow WE; Minasian LM; Unger J
    J Clin Oncol; 2016 Sep; 34(25):3014-22. PubMed ID: 27325863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
    Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
    Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
    Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
    Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
    Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
    J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
    Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
    Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
    Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.
    Sánchez-Barroso L; Apellaniz-Ruiz M; Gutiérrez-Gutiérrez G; Santos M; Roldán-Romero JM; Curras M; Remacha L; Calsina B; Calvo I; Sereno M; Merino M; García-Donas J; Castelo B; Guerra E; Letón R; Montero-Conde C; Cascón A; Inglada-Pérez L; Robledo M; Rodríguez-Antona C
    Oncologist; 2019 Aug; 24(8):e784-e792. PubMed ID: 30470691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
    Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
    Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced peripheral neuropathy: Current status and progress.
    Brewer JR; Morrison G; Dolan ME; Fleming GF
    Gynecol Oncol; 2016 Jan; 140(1):176-83. PubMed ID: 26556766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Falls in persons with chemotherapy-induced peripheral neuropathy.
    Tofthagen C; Overcash J; Kip K
    Support Care Cancer; 2012 Mar; 20(3):583-9. PubMed ID: 21380613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.
    Rose PG; Smrekar M
    Gynecol Oncol; 2003 Nov; 91(2):423-5. PubMed ID: 14599877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
    Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
    Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
    Guo Y; Jones D; Palmer JL; Forman A; Dakhil SR; Velasco MR; Weiss M; Gilman P; Mills GM; Noga SJ; Eng C; Overman MJ; Fisch MJ
    Support Care Cancer; 2014 May; 22(5):1223-31. PubMed ID: 24362907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
    Greenwald MK; Ruterbusch JJ; Beebe-Dimmer JL; Simon MS; Albrecht TL; Schwartz AG
    Cancer; 2019 Jan; 125(2):269-277. PubMed ID: 30387871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.
    Chase DM; Huang H; Foss CD; Wenzel LB; Monk BJ; Burger RA
    Gynecol Oncol; 2015 Feb; 136(2):323-7. PubMed ID: 25529832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
    Thomaier L; Darst BF; Jewett P; Hoffmann C; Brown K; Makaram A; Blaes A; Argenta P; Teoh D; Vogel RI
    Gynecol Oncol; 2021 Dec; 163(3):578-582. PubMed ID: 34674889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
    Tanishima H; Tominaga T; Kimura M; Maeda T; Shirai Y; Horiuchi T
    Support Care Cancer; 2017 May; 25(5):1383-1389. PubMed ID: 27921224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study.
    Kus T; Aktas G; Kalender ME; Sevinc A; Kul S; Suner A; Ulker E; Camci C
    Support Care Cancer; 2016 Mar; 24(3):1175-9. PubMed ID: 26279147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.